P @ Work

Progress at Work - The Impact of an Active Drug on Work Related Productivity in Patients With Rheumatoid Arthritis

Brief summary

The purpose of this study is to describe the impact of treatment with an active drug on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.

Observational study

Rheumatoid Arthritis
401 patients
Protocol ID:
Observational model:
Time perspective:

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female


From 18 Years to 99 Years.

Inclusion Criteria:

1. Subjects with moderate to severe RA for whom the physician has decided to initiate
treatment with adalimumab

2. Adult male or female ≥ 18 years old that has been newly prescribed adalimumab therapy
according to the local product label and are with PROGRESS

3. Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active
and latent TB

4. Subject is able to give written patient authorization and is willing to comply with
the requirements of this study protocol.

Exclusion Criteria:

1. Subject cannot or will not sign a patient authorization

2. Subject with a known hypersensitivity to Adalimumab, or any of its components

3. Presence of any condition that, in the opinion of the treating physician, prohibits
the subject from participating in the study or obscures the assessment of the
treatment of RA

4. Subjects currently participating in an investigational clinical trial

5. Subjects treated with >1 prior biologic disease-modifying antirheumatic drugs (DMARDs)
for RA. Any prior treatment with adalimumab is prohibited

6. Subjects previously treated with targeted synthetic disease modifying agent.

All the cities where the clinical studies are located